The digital transformation in pathology is well underway but what kind of opportunities does this present to us? We've heard all the buzz words such as machine learning artificial intelligence and heard all the hype about enhanced workflows and making pathologists’ lives easier. What is the future practice of pathology going to look like? Our guest is Beatrice Knudsen, MD, PhD, Medical Director of Digital and Computational Pathology at ARUP Laboratories, as well as Professor of Pathology at the University of Utah. Dr. Knudsen has built a program that integrates histopathology, multiplex tissue staining, digital image analysis, as well as computational pathology. She is applying this approach to close the gap between laboratory research and clinical care and to develop novel algorithms for diagnosis, prognosis and the treatment of patients.

They're coming - AI and machine learning algorithms in digital pathology. How do we go about assessing the robustness and suitability of these new tool for use in actual clinical practice? Our guests are Dr. Angelique Levi, Associate Professor of Pathology and Vice Chair and Director of Pathology Outreach Services and Dr. Sudhir Perincheri, Assistant Professor of Pathology and Director of Digital Pathology, both from Yale School of Medicine. We're talking about how new tools are going to be incorporated into clinical practice, and the impact of these new tools in various practice settings, such as academic medical centers, community outreach, and private practice. What does this mean for the training of the next generation of pathologists? We're only human, after all, but what about machine algorithms? What level of mistakes or "misses" is allowable? And what if these tools are too sensitive, could they actually slow us down and make life more complicated for us?

Too many systems or components in a pathology workflow adds complexity and cost. How can we create an elegant end to end solution to enhance workflows, while decreasing both complexity and costs? Our guest is John Wirthlin, CEO of Lumea, a company reimagining pathology - beginning and ending with the patient. We discuss the end-to-end solution in digital pathology. One of the promises of digital pathology is making the pathologist’s workflow more streamlined and more efficient. But can we bring the Laboratory Information System (LIS) into the clinic and improve the workflow flow for our clinician colleagues as well. How can we improve the tissue handling or preanalytic phase of testing? It's often easy to forget who the customer is. By utilizing enhanced workflows, can we improve satisfaction for the clinician, who is ultimately treating the patient?

Amidst this digital transformation in pathology the talk seems to be largely centered around whole slide imaging of H&E-stained tissue sections. But what about cytology? Why don't we hear much talk about digital cytology, and what are some of the unique challenges in cytology in terms of going digital. Our guest is Michael Quick, Vice President of Research and Development and Innovation at Hologic. We discuss the history and evolution of cervical cancer screening all the way from pap smears to thin prep to incorporating digital pathology and image analysis in the process. Will we finally be able to say goodbye to the light microscope? And what are some of the parallels and lessons learned comparing cervical cancer screening by cytology in pathology to breast cancer screening by digital mammography in radiology.

What is going to surprise us in digital pathology in big ways and in small ways? How can seemingly small changes make a big impact in what we do as pathologists and in the lives of patients? How are we going to make use of the large datasets that we will inevitably be generating through the widescale adoption of digital pathology? Our guest is Louis Culot, General Manager for Genomics and Oncology Informatics at Phillips. We're going to be talking about the current landscape of digital pathology in 2022, where we've been in the past 20 years and even earlier, and the impact of the COVID-19 global health emergency on the acceleration of the adoption of digital pathology. And what is the future of integrated diagnostics, incorporating digital pathology radiology and molecular diagnostics.

It's easy to get caught up in the hype surrounding digital pathology. But what is actually involved and going digital? What are the steps involved? We know about scanners and viewing images, of course. But what other pieces of software might be necessary or helpful? Coleman Stavish is co-founder and CTO at Proscia, a leading provider of digital and computational pathology solutions. At Proscia, Coleman works with a team of engineers and scientists who develop enterprise software in use at leading laboratories and large biopharma companies around the world, as well as novel image classification. We're going to be talking about workflows in digital pathology and the importance of the image management platform. What are the considerations in going digital, how can all of our software work together and how can we truly realize the promise of digital pathology by incorporating AI algorithms and other tools?

NVIDIA is involved in computer graphics, artificial intelligence, computing and processors across variety of industries including gaming, entertainment, finance, and health care. What are the commonalties of all these industries and what lesson from other fields can we apply to healthcare? Our guest is Craig Rhodes EMEA Industry Lead - AI for Healthcare and Life Sciences at NVIDIA. There is the perception that healthcare lags other industries in terms of AI applications. Is this true or is it a misconception? How is AI changing healthcare now and for the future How can we accelerate the adoption of AI and new technologies in health care? NVIDIA has launched Cambridge-1 - a powerful supercomputer in the UK. We will learn about this and what results we can expect from Cambridge one in the difference this will make in healthcare in the lives of patients.

Our guests are Dr. Garth Bryson Consultant Pathologist and Clinical Director for Laboratory Medicine at the NHS Greater Glasgow and Clyde and Dr. David Harrison, Professor of Pathology from the University of Saint Andrews, and both from ICAIRD - the Industrial Center for Artificial Intelligence Research and Digital Diagnostics a program matching AI solutions and research with health and social care priorities across Scotland. We talk about the long journey of implementing digital pathology in a large health care system, barriers to adoption of digital pathology, the promise of artificial intelligence, the business case for digital pathology – have we finally been able to articulate one? And finally, we discuss our guests’ experience so far in creating a digital slide sharing network throughout Scotland.

Our guest is one of the giants in the field of digital pathology and image analysis. And if he has seen further than others, he will tell you, it is because he was able to stand on the shoulders of giants as well. His unique multidisciplinary approach has allowed him to breakdown silos and see across the often-artificial barriers and distinctions imposed by academic disciplines and patient treatment paradigms. We're talking with Professor Anant Madabhushi, Director of the Center for Computational Imaging and Personalized Diagnostics and Professor of Biomedical Engineering, Radiology, Pathology Urology and Radiation Oncology at Case Western Reserve University. We discuss silos in academic departments and disease states and how looking beyond these limitations can propel progress. What exactly is image analysis, what if we've been able to do with it so far and what predictive and prognostic information can we unlock from histologic features. And finally, how can an image analysis and non-tissue destructive computational and AI powered methods help to democratize access to care and lead to better outcomes for patients across the world.

What have we been waiting for? What's taking so long? Much of the technology surrounding digital pathology has been with us for over 20 years. After fits and starts and initial excitement we've been left with disappointment in the past ten years. But now, it seems like the tide is turning and the digital transformation is here. Our guest is Richard Lash, MD, Chief Medical Officer from Lumea, a company re-imagining pathology by developing a comprehensive end to end workflow. Dr. Lash has had a long career as a pathologist as well as holding leadership positions in addition to Lumea at several prominent organizations including Inform Diagnostics, Ameripath and Mount Sinai Medical Center. We're going to be talking about how the lack of a cohesive business for digital pathology, lack of a vision to integrate exciting new technologies into everyday workflows has hindered the adoption of digital pathology; what has changed and why now with compelling new technologies including artificial intelligence, we can finally begin to develop and incorporate end to end solutions that can enhance pathologist performance and improve outcomes for doctors and patients.